SGMO / Sangamo Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 SANGAMO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 SANGAMO THERAPEUTICS, INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on August 8, 2025

S-8 As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2025 FINANCIAL RESULTS Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2025 FINANCIAL RESULTS Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 SANGAMO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc.

Exhibit 10.1 Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated by the Compensation Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 SANGAMO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Form of Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed May 12, 2025).

Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: May [ ], 2025 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitati

Form of Purchase Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed May 12, 2025).

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: May [ ], 2025 (such date, the “Issue Date”) This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 SANGAMO THERAPEUTICS

false0001001233NASDAQ00010012332025-05-122025-05-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

SANGAMO THERAPEUTICS, INC. 12,235,000 Shares of Common Stock par value $0.01 per share Pre-Funded Warrants to Purchase up to 34,398,393 Shares of Common Stock Warrants to Purchase up to 46,633,393 Shares of Common Stock Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION SANGAMO THERAPEUTICS, INC. 12,235,000 Shares of Common Stock par value $0.01 per share Pre-Funded Warrants to Purchase up to 34,398,393 Shares of Common Stock Warrants to Purchase up to 46,633,393 Shares of Common Stock Underwriting Agreement May 12, 2025 CANTOR FITZGERALD & CO. As Representative of the several Underwriters listed in Schedule 1 hereto c/o Cantor Fitzg

Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Warrants to Purchase Shares of Common Stock

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated May 12, 2025 Relating to Prospectus Dated November 19, 2024 Registration Statement No.

12,235,000 Shares of Common Stock Pre-Funded Warrants to Purchase 34,398,393 Shares of Common Stock Warrants to Purchase 46,633,393 Shares of Common Stock

TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-283179 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 19, 2024)   12,235,000 Shares of Common Stock Pre-Funded Warrants to Purchase 34,398,393 Shares of Common Stock Warrants to Purchase 46,633,393 Shares of Common Stock We are offering (i) 12,235,000 shares of our common stock, pre-funded warrants to purchase 34,398,3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC

Subsidiaries of the Company.

Exhibit 21.1 Subsidiaries of the Company The following is a list of subsidiaries of the Company as of December 31, 2024 omitting a subsidiary which would not constitute a significant subsidiary. Gendaq Limited (U.K.) Sangamo Therapeutics France S.A.S. (France)

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements wi

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 20

Description of Capital Stock

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Sangamo,” “our,” “we,” “us” and the “Company” refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. General Our restated certificate of incorporation, or the Restated Certificate, authorizes us to issue 960,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par val

Insider Trading Policy.

Exhibit 19.1 SANGAMO THERAPEUTICS, INC. INSIDER TRADING POLICY This Insider Trading Policy of Sangamo Therapeutics, Inc. and its subsidiaries (“Sangamo” or the “Company”) outlines the restrictions and procedures that all Sangamo personnel must follow. Failure to comply with these restrictions and procedures could result in a serious violation of the securities laws by you and/or Sangamo and can in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 SANGAMO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 SANGAMO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 SANGAMO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

1 1053 Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Primary Analysis Results From the Phase 3 AFFINE Gene Therapy Trial Andrew D Leavitt1, Kaan Kavakli2, Laurent Frenzel3, Ali Bülent Antm

a66thamericansocietyofhe 1 1053 Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Primary Analysis Results From the Phase 3 AFFINE Gene Therapy Trial Andrew D Leavitt1, Kaan Kavakli2, Laurent Frenzel3, Ali Bülent Antmen4, Margareth Ozelo5, Davide Matino6,7, Hazza Alzahrani8, Barbara A Konkle9, Steven W Pipe10, Jerome M Teitel11, Li-Jung Tse

SANGAMO THERAPEUTICS, INC. 501 Canal Blvd. Richmond, California 94804

SANGAMO THERAPEUTICS, INC. 501 Canal Blvd. Richmond, California 94804 November 18, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama RE: Sangamo Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-283179 Acceleration Request Requested Date: November 19, 2024 Requested Time

Sangamo Therapeutics, Inc. _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ SANGAMO THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT

Exhibit 4.7 Sangamo Therapeutics, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of SANGAMO THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organiz

Sangamo Therapeutics, Inc. _____________, As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of __________ SANGAMO THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT

Exhibit 4.6 Sangamo Therapeutics, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of SANGAMO THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organiz

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Third Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated July 3, 2024.

THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is entered into as of July 3, 2024, (the “Third Amendment Effective Date”), by and between PPF OFF 7000 MARINA BOULEVARD LP, a Delaware limited partnership (“Landlord”), and SANGAMO THERAPEUTICS, INC.

Sangamo Therapeutics, Inc. _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ SANGAMO THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT

Exhibit 4.5 Sangamo Therapeutics, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of SANGAMO THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and ex

Amendment No. 4 to the Open Market Sale Agreement between the Company and Jefferies LLC, dated November 12, 2024 (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 filed November 12, 2024).

Exhibit 1.2 AMENDMENT NO. 4 TO OPEN MARKET SALE AGREEMENTSM November 12, 2024 This Amendment No. 4 (“Amendment No. 4”) amends that certain Open Market Sale AgreementSM, dated as of August 5, 2020, as amended by Amendment No. 1 (“Amendment No. 1”) to Open Market Sale AgreementSM, dated as of May 5, 2021, Amendment No. 2 (“Amendment No. 2”) to Open Market Sale AgreementSM, dated as of December 23, 2

As filed with the Securities and Exchange Commission on November 12, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 12, 2024 Registration No.

Calculation of Filing Fee Table Form S-3 (Form Type) Sangamo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sangamo Therapeutics, Inc.

SANGAMO THERAPEUTICS, INC., Dated as of [•], 20__ Debt Securities Table Of Contents

Exhibit 4.3 SANGAMO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8

License Agreement between the Company and Genentech, Inc., dated August 2, 202

Confidential Execution Version Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential. LICENSE AGREEMENT BETWEEN SANGAMO THERAPEUTICS, INC. AND GENENTECH, INC. AS OF AUGUST 2, 2024 Confidential Execution Version TABLE OF CONTENTS

As filed with the Securities and Exchange Commission on November 12, 2024

As filed with the Securities and Exchange Commission on November 12, 2024 Registration No.

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, u

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Calculation of Filing Fee Table Form S-8 (Form Type) Sangamo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sangamo Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 SANGAMO THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commiss

RLF1 31428982v.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE SANGAMO THERAPEUTICS, INC. ) ) ) C.A. No. 2024-____-___ VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. § 205 Petitioner Sangamo Therapeutics, Inc. (“Sangamo” or the “Company

section205verifiedpetiti RLF1 31428982v.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE SANGAMO THERAPEUTICS, INC. ) ) ) C.A. No. 2024- VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. § 205 Petitioner Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a c

SGMO / Sangamo Therapeutics, Inc. / BIOGEN INC. - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SANGAMO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 800677106 (CUSIP Number) August 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS •Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in

SANGAMO THERAPEUTICS REPORTS ON PFIZER'S ANNOUNCEMENT OF POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF HEMOPHILIA A GENE THERAPY CANDIDATE Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophy

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS ON PFIZER'S ANNOUNCEMENT OF POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF HEMOPHILIA A GENE THERAPY CANDIDATE Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis RICHMOND, California, July 24, 2024 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported on Pfiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 SANGAMO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 SANGAMO THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc.

ex-101amendedandrestated 1. Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated by the Com

Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 5, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. Sangamo Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: First: The name of the Corporation is Sangamo Therapeutics, Inc. (the “Corporation”). Second: The date of filing of the Res

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS •Showcased 20 presentations at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrier

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SANGAMO THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Second Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated February 5, 2024.

SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is entered into as of February 5, 2024, (the “Second Amendment Effective Date”), by and between PPF OFF 7000 MARINA BOULEVARD LP, a Delaware limited partnership (“Landlord”), and SANGAMO THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

24,761,905 Shares of Common Stock Pre-Funded Warrants to Purchase 3,809,523 Shares of Common Stock Warrants to Purchase 28,571,428 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255792 PROSPECTUS SUPPLEMENT (To Prospectus dated April 21, 2023) 24,761,905 Shares of Common Stock Pre-Funded Warrants to Purchase 3,809,523 Shares of Common Stock Warrants to Purchase 28,571,428 Shares of Common Stock We are offering (i) 24,761,905 shares of our common stock, pre-funded warrants to purchase 3,809,523 s

Form of Securities Purchase Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and the purchasers party thereto.

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2024, between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the t

Form of Pre-Funded Warrant to Purchase Common Stock.

EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: March 26, 2024 (such date, the “Issue Date”) Warrant No.: PF-[  ] This PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the

Form of Warrant to Purchase Common Stock.

EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: March 26, 2024 (such date, the “Issue Date”) This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions

Placement Agent Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and Barclays Capital Inc. and Cantor Fitzgerald & Co.

EX-10.2 Exhibit 10.2 SANGAMO THERAPEUTICS, INC. 24,761,905 Shares of Common Stock par value $0.01 per share Pre-Funded Warrants to Purchase up to 3,809,523 Shares of Common Stock Warrants to Purchase 28,571,428 Shares of Common Stock Placement Agent Agreement March 21, 2024 BARCLAYS CAPITAL INC. CANTOR FITZGERALD & CO.  As Placement Agents c/o Barclays Capital Inc. 745 Seventh Avenue New York, New

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Sangamo,” “our,” “we,” “us” and the “Company” refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. General Our restated certificate of incorporation, or the Restated Certificate, authorizes us to issue 640,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par val

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS •Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

Subsidiaries of the Company.

Exhibit 21.1 Subsidiaries of the Company The following is a list of subsidiaries of the Company as of December 31, 2023 omitting a subsidiary which would not constitute a significant subsidiary. Gendaq Limited (U.K.) Sangamo Therapeutics France S.A.S. (France)

Letter Agreement Regarding Prathyusha Duraibabu Cash Retention Award

Prathyusha Duraibabu Dear Prathyusha: Success-Based Cash Retention Award Opportunity You are eligible to earn a special cash retention award in the maximum aggregate amount of $193,584 (which is equal to 100% of your Annual Bonus Target amount), less applicable payroll withholdings and deductions, pursuant to the terms and conditions set forth in this letter (“Cash Retention Award”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC

Letter Agreement Regarding Alexander (Sandy) Macrae Cash Retention Award

Alexander “Sandy” Macrae Dear Sandy: Success-Based Cash Retention Award Opportunity You are eligible to earn a special cash retention award in the maximum aggregate amount of $429,820 (which is equal to 100% of your Annual Bonus Target amount), less applicable payroll withholdings and deductions, pursuant to the terms and conditions set forth in this letter (“Cash Retention Award”).

Incentive Compensation Recoupment Policy

October 16, 2023 Version 1.0 Incentive Compensation Recoupment Policy This document may contain proprietary and confidential information. It is strictly for internal Sangamo use and may not be disseminated outside of Sangamo. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc., a Delaware corporation (the “Com

SGMO / Sangamo Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01874-sangamotherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Sangamo Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 800677106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

SGMO / Sangamo Therapeutics, Inc. / BIOGEN INC. - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SANGAMO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 800677106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 SANGAMO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

1 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) , December 9–12, 2023, San Diego, CA, USA Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Ad

1 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) , December 9–12, 2023, San Diego, CA, USA Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A Thomas J Harrington1, Adam Giermasz2, Nathan Visweshwar3, Andrew D Leavitt4, Barbara A Konkle5, Jeremy Rupon6, Gregory D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 SANGAMO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Amended and Restated Severance Plan of Sangamo Therapeutics, Inc.

SANGAMO THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN INTRODUCTION The Sangamo Therapeutics, Inc. Amended and Restated Executive Severance Plan (the “Plan”) is amended and restated effective as of October 28, 2023 (the “Effective Date”). The Plan was previously amended and restated effective as of February 6, 2019, which amended and restated in its entirety the Company’s Executi

SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS •Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. •Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. •Dosed a total of 25 patients in Ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

As filed with the Securities and Exchange Commission on August 8, 2023

As filed with the Securities and Exchange Commission on August 8, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

Filing fee table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sangamo Therapeutics, Inc.

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS Conference call and webcast scheduled for Tuesday August 8, 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS Conference call and webcast scheduled for Tuesday August 8, 4:30 p.m. Eastern Time Brisbane, California, August 8, 2023 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results. “I am extr

Sixth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation of Sangamo Therapeutics, Inc.

Exhibit 3.2 SIXTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. Sangamo Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: First: The name of the Corporation is Sangamo Therapeutics, Inc. (the “Corporation”). Second: The

Fifth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation of Sangamo Therapeutics, Inc.

Exhibit 3.1 FIFTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. Sangamo Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: First: The name of the Corporation is Sangamo Therapeutics, Inc. (the “Corporation”). Second: The

Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 2, 2023).

sgmo2018eiparmarch2023 286911297 v2 1. Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 SANGAMO THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed June 2, 2023).

Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. a Delaware Corporation Sangamo Therapeutics, Inc., a corporation organized and existing under the General Corporation law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: The name of the Corporation is Sangamo Therapeutics, Inc. SECOND: The Original Certificate of Incorporation of said Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS •Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. •Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. •Unveiled Nav1.7 target to treat chronic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 SANGAMO THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

Amendment No. 3 to Open Market Sale Agreement between the Company and Jefferies LLC, dated March 7, 2023 (incorporated by reference to Exhibit 1.1 to the Company’s Quarterly Report on Form 10-Q filed May 8, 2023).

EX-1.1 2 exhibit11-amendmentno3toop.htm EX-1.1 Exhibit 1.1 AMENDMENT NO. 3 TO OPEN MARKET SALE AGREEMENTSM March 7, 2023 This Amendment No. 3 (“Amendment No. 3”) amends that certain Open Market Sale AgreementSM, dated as of August 5, 2020, as amended by Amendment No. 1 (“Amendment No. 1”) to Open Market Sale AgreementSM, dated as of May 5, 2021, and Amendment No. 2 (“Amendment No. 2”) to Open Mark

$204,119,827.69 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255792 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 22, 2023) $204,119,827.69 Common Stock We have entered into an Open Market Sale AgreementSM with Jefferies LLC, or Jefferies, dated August 5, 2020, as amended by Amendment No. 1 to Open Market Sale AgreementSM, dated May 5, 2021, Amendment No. 2 to Open Market Sa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 SANGAMO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 SANGAMO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Sangamo,” “our,” “we,” “us” and the “Company” refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. General Our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 320,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 sh

Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 201

exhibit1053-pfizersb525l Exhibit 10.53 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT by and between Sangamo Therapeutics, Inc. and Pfizer Inc. May 10, 2017 2 [*] = Certain confidential information contained

As filed with the Securities and Exchange Commission on February 23, 2023

S-8 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No.

As filed with the Securities and Exchange Commission on February 23, 2023

POS AM Table of Contents As filed with the Securities and Exchange Commission on February 23, 2023 Registration No.

Subsidiaries of the Company.

Exhibit 21.1 Subsidiaries of the Company Gendaq Limited (U.K.) Ceregene Inc. (Delaware) Sangamo Therapeutics France S.A.S. (France)

Filing fee table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sangamo Therapeutics, Inc.

Filing fee table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sangamo Therapeutics, Inc.

Power of Attorney (incorporated by reference to the signature pages to the Registrant’s Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-255792) filed February 22, 2023).

POSASR 1 d468999dposasr.htm POSASR Table of Contents As filed with the Securities and Exchange Commission on February 22, 2023 Registration No. 333-255792 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 SANGAMO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, February 22, 2023 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial result

SGMO / Sangamo Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Sangamo Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 800677106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

Amendment No. 2 to Open Market Sale Agreement between the Company and Jefferies LLC, dated December 23, 2022 (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed December 23, 2022).

Exhibit 1.1 AMENDMENT NO. 2 TO OPEN MARKET SALE AGREEMENT December 23, 2022 This Amendment No. 2 (?Amendment No. 2?) amends that certain Open Market Sale AgreementSM, dated as of August 5, 2020, as amended by Amendment No. 1 (?Amendment No. 1?) to Open Market Sale AgreementSM, dated as of May 5, 2021 (the ?Agreement?), by and between Sangamo Therapeutics, Inc. (the ?Company?) and Jefferies LLC, as

Calculation of Filing Fee Table (Form Type) Sangamo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Maximum Aggregate Offering Pric

Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Sangamo Therapeutics, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

$175,000,000 Common Stock

424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-255792 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 5, 2021) $175,000,000 Common Stock We have entered into Amendment No. 2, dated December 23, 2022, to the Open Market Sale AgreementSM with Jefferies LLC, or Jefferies, dated August 5, 2020, as previously amended on May 5, 2021, or the sales agreement, to increase t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 19, 2022).

sgmo-20221219xxex31fifth EXHIBIT 3.1 1 FIFTH AMENDED AND RESTATED BYLAWS OF SANGAMO THERAPEUTICS, INC. ARTICLE I CERTIFICATE OF INCORPORATION AND BYLAWS Section 1. These Bylaws are subject to the Certificate of Incorporation of the Corporation, as amended and/or restated to date. In these Bylaws, references to law, the Certificate of Incorporation and Bylaws mean the law, the provisions of the Cer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 SANGAMO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, November 3, 2022 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. ?This has been a year marked

Letter Agreement between the Company and Nathalie Dubois-Stringfellow dated as of September 28, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 3, 2022).

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (?Agreement?) made as of the 28th day of September 2022 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the ?Company?), and Nathalie Dubois-Stringfellow (?Executive?) (collectively, the ?Parties?). R E C I T A L S WHEREAS, the Company desires to promote Ms. Dubois-Stringfellow to Senior Vice President, Chief Develo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 SANGAMO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Comm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, August 4, 2022 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. ?We made meaningful progress

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc

Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated by the Compensation Committee of the B

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2022 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, May 5, 2022 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results. ?This quarter, we have continued

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

Amended and Restated Office and Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated October 18, 2021 (incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K filed February 24, 2022).

AMENDED AND RESTATED OFFICE/LABORATORY LEASE BETWEEN POINT RICHMOND R&D ASSOCIATES II, LLC (LANDLORD) AND SANGAMO THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Agreement between the Company and

Exhibit 10.34 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (?Agreement?) made effective as of the 1st day of November 2021 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the ?Company?), and David Mark McClung (?Executive?) (collectively, the ?Parties?). R E C I T A L S WHEREAS, the Company desires to promote Mr. McClung to Executive Vice President, Chief Operating Office

Subsidiaries of the Company

EX-21.1 4 sgmo-20211231xexx211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Company Gendaq Limited (U.K.) Ceregene Inc. (Delaware) Sangamo Therapeutics France S.A.S. (France)

SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, February 24, 2022 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlight

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC

SGMO / Sangamo Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Sangamo Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 800677106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS AND CLINICAL HIGHLIGHTS AND THIRD QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 9:15 a.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS AND CLINICAL HIGHLIGHTS AND THIRD QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 9:15 a.m. Eastern Time Brisbane, California, November 4, 2021 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights. ?We ar

Letter Agreement between the Company and

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (?Agreement?) made effective as of the 2nd day of August 2021 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the ?Company?), and Scott B. Willoughby (?Executive?) (collectively, the ?Parties?). R E C I T A L S WHEREAS, the Company desires to promote Mr. Willoughby to Executive, and Executive desires to be promoted

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Letter Agreement between the Company and

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (?Agreement?) made as of the 21st day of May 2021 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the ?Company?), and Prathyusha Duraibabu (?Executive?) (collectively, the ?Parties?). R E C I T A L S WHEREAS, the Company desires to promote Ms. Duraibabu to Executive, and Executive desires to be promoted by the Comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Brisbane, California, August 5, 2021 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. ?This is an exciting time at

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of inco

- S-3ASR

Table of Contents As filed with the Securities and Exchange Commission on May 5, 2021 Registration No.

Form of Debt Securities Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.7 to the Registrant’s Registration Statement on Form S-3 (File No. 333-255792) filed May 5, 2021).

Exhibit 4.7 SANGAMO THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SANGAMO THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SANGAMO THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz

Amendment No. 1 to Open Market Sale Agreement, dated May 5, 2021, between the Registrant and Jefferies LLC.

Exhibit 1.3 AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENT May 5, 2021 This Amendment No. 1 (?Amendment No. 1?) amends that certain Open Market Sale AgreementSM, dated as of August 5, 2020 (the ?Agreement?), by and between Sangamo Therapeutics, Inc. (the ?Company?) and Jefferies LLC, as sales agent and/or principal (the ?Agent?). Defined terms used herein and not otherwise defined shall have the me

Form of Indenture, between Registrant and one or more trustees to be named (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-3 (File No. 333-255792) filed May 5, 2021).

Exhibit 4.3 SANGAMO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Exhibit 4.3TOC TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s

Form of Common Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form S-3 (File No. 333-255792) filed May 5, 2021).

Exhibit 4.5 SANGAMO THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF Exhibit 4.5 SANGAMO THERAPEUTICS, INC. FORM OF COMMON STOCK WARRNT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SANGAMO THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organ

Form of Preferred Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.6 to the Registrant’s Registration Statement on Form S-3 (File No. 333-255792) filed May 5, 2021).

Exhibit 4.6 SANGAMO THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SANGAMO THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SANGAMO THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz

Letter Agreement between the Company and

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2021 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Brisbane, California, May 4, 2021 ? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results. ?This quarter, we have continued o

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Letter Agreement between the Company and

EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (?Agreement?) made as of the 6th day of January 2021 by and between Sangamo Therapeutics, Inc.

Ninth Amendment to Triple Net Laboratory Lease

NINTH AMENDMENT TO LEASE THIS NINTH AMENDMENT TO LEASE (this ?Ninth Amendment?) is entered into as of January 4, 2021, by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (?Landlord?), and SANGAMO THERAPEUTICS, INC.

- DEF 14A

DEF 14A 1 sgmoproxyx2021xdefxvs.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

EX-99.1 2 exhibit-9911231.htm EX-99.1 Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Brisbane, California, February 24, 2021 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial

Description of

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to ?Sangamo,? ?our,? ?we,? ?us? and the ?Company? refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. General Our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 320,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 sh

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company Gendaq Limited (U.K.) Ceregene Inc. (Delaware) Sangamo Therapeutics France S.A.S. (France)

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)*

SC 13G/A 1 tv01778-sangamotherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Sangamo Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 800677106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* SANGAMO BIOSCIENCES INC (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

Letter Agreement between the Company and Sung Lee dated as of January 22, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 28, 2021).

Exhibit 10.1 January 22, 2021 Mr. Sung Lee Dear Sung: Your last day as a Sangamo employee will be February 1, 2021 (“Separation Date”). We are sad to see you leave Sangamo, but are grateful for your time of accomplished service. We are also pleased that you are willing to continue working with Sangamo in an independent contractor role for the period from February 2, 2021 through February 26, 2021.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Disclosures for: Andrew D. Leavitt, MD Conflict Disclosure Research Support None Director, Officer, Employee None Shareholder Johnson & Johnson Honoraria None Advisory Committee BioMarin; Dova Pharmaceuticals; Catalyst Biosciences; Bio Products Labor

EX-99.1 Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults With Severe Hemophilia A Andrew D. Leavitt, MD1; Barbara A. Konkle, MD2,3; Kimo Stine, MD4; Nathan Visweshwar, MD5; Thomas J. Harrington, MD6; Adam Giermasz, MD, PhD7; Steven Arkin, MD8; Annie Fang, MD, PhD9; Frank Plonski, RN, MA8; Lynne Smith, MBA10; Li-Jung Tseng, PhD, MBA9; Grego

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Fourth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 15, 2020).

EX-3.1 EXHIBIT 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF SANGAMO THERAPEUTICS, INC. ARTICLE I CERTIFICATE OF INCORPORATION AND BYLAWS Section 1. These Bylaws are subject to the Certificate of Incorporation of the Corporation, as amended and/or restated to date. In these Bylaws, references to law, the Certificate of Incorporation and Bylaws mean the law, the provisions of the Certificate of Incorpo

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Disclosures for: Andrew D. Leavitt, MD Conflict Disclosure Research Support None Director, Officer, Employee None Shareholder Johnson & Johnson Honoraria None Advisory Committee BioMarin; Dova Pharmaceuticals; Catalyst Biosciences; Bio Products Labor

EX-99.2 Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults With Severe Hemophilia A Andrew D. Leavitt, MD1; Barbara A. Konkle, MD2,3; Kimo Stine, MD4; Nathan Visweshwar, MD5; Thomas J. Harrington, MD6; Adam Giermasz, MD, PhD7; Steven Arkin, MD8; Annie Fang, MD, PhD9; Frank Plonski, RN, MA8; Lynne Smith, MBA10; Li-Jung Tseng, PhD, MBA9; Grego

###

EX-99.1 Exhibit 99.1 PFIZER AND SANGAMO ANNOUNCE UPDATED PHASE 1/2 RESULTS SHOWING SUSTAINED FACTOR VIII ACTIVITY LEVELS IN 3E13 VG/KG COHORT THROUGH ONE YEAR FOLLOWING HEMOPHILIA A GENE THERAPY - First patient was dosed in pivotal Phase 3 AFFINE study in October 2020 New York, NY, and Brisbane, California – December 7, 2020 – Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO),

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

Collaboration and License Agreement between the Company and Novartis Institutes for BioMedical Research, Inc., dated July 27, 2020 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed November 4, 2020).

Exhibit 10.2 Confidential Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT by and between Sangamo Therapeutics, Inc. and Novartis Institutes for BioMedical Research, Inc. July 27, 2020 Confide

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commis

SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND THIRD QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND THIRD QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Brisbane, California, November 4, 2020 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “We are pleased with the clinical ex

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Amendment No. 2 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated July 31, 2020 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed November 4, 2020).

Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Amendment No. 2 to Agreement (“Amendment No. 2”) Amendment No. 2 Date: 31 July 2020 Name of Original Agreement: Research Collaboration and License Agreement (the “Agreement”) Effective Date

- S-8

S-8 As filed with the Securities and Exchange Commission on October 14, 2020 Registration No.

2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed October 15, 2020).

EX-99.1 Exhibit 99.1 SANGAMO THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD: SEPTEMBER 18, 2020 1. GENERAL. (a) Purpose. The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of Employees and to provide incentives for such persons to exert maximum efforts for the success of the

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.01 per share $150,000,000 $19,470(1)

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224418 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.01 per share $150,000,000 $19,470(1) (1) The filing fee is calculated and being paid pursuant to Rule 457(r) under the Securities Act of 1933, as amen

Employment Agreement between the Company and Mark McClung effective as of April 13, 2020.

EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (“Agreement”) made as of the 13th day of April, 2020 by and between Sangamo Therapeutics, Inc.

- S-8

S-8 As filed with the Securities and Exchange Commission on August 5, 2020 Registration No.

Seventh Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 20, 2020 (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).

SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (this “Seventh Amendment”) is entered into as of May 20, 2020 (the “Effective Date”), by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (“Landlord”), and SANGAMO THERAPEUTICS, INC.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000

Letter Agreement Regarding Andrew Ramelmeier Special Bonus (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).

Dear Andy: The Executive Leadership Team recognizes your recent contributions and the critical importance of your leadership and experience to Sangamo’s manufacturing strategy.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND SECOND QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND SECOND QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Brisbane, California, August 5, 2020 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights. “We are very excited about our globa

Open Market Sale Agreement between the Company and Jefferies LLC, dated August 5, 2020 (incorporated by reference to Exhibit 1.1 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).

OPEN MARKET SALE AGREEMENT1 August 5, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Sangamo Therapeutics, Inc.

Eighth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 29, 2020 (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).

EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (this “Eighth Amendment”) is entered into as of May 29, 2020 (the “Effective Date”), by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (“Landlord”), and SANGAMO THERAPEUTICS, INC.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissio

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

EX-99.1 Exhibit 99.1 For Immediate Release Pfizer Media Contact: Steve Danehy June 18, 2020 212-733-1538 [email protected] Pfizer Investor Contact: Chuck Triano 212-733-3901 [email protected] Sangamo Media Contact: Aron Feingold 510-970-6000, x421 [email protected] Sangamo Investor Contact: McDavid Stilwell 510-970-6000, x219 [email protected] Pfizer and Sangamo Announce U

Disclosures for: Thomas J. Harrington, MD Conflict Disclosure Research Support Sangamo/Pfizer Inc. Director, Officer, Employee none Shareholder none Honoraria none Advisory Committee none Consultant none

EX-99.2 Updated Follow-up of the High-Dose Cohort in the Alta Study, a Phase 1/2 Study of giroctocogene fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia A Thomas J. Harrington, MD1; Barbara A. Konkle, MD2; Kimo Stine, MD3; Nathan Visweshwar, MD4; Andrew D. Leavitt, MD5; Adam Giermasz, MD, PhD6; Steven Arkin, MD7; Annie Fang, MD, PhD8; Li-Jung Tseng, MBA, PhD8; Gregory Di Russo,

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commiss

Disclosures for: Thomas J. Harrington, MD Conflict Disclosure Research Support Sangamo/Pfizer Inc. Director, Officer, Employee none Shareholder none Honoraria none Advisory Committee none Consultant none

EX-99.2 Updated Follow-up of the High-Dose Cohort in the Alta Study, a Phase 1/2 Study of giroctocogene fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia A Thomas J. Harrington, MD1; Barbara A. Konkle, MD2; Kimo Stine, MD3; Nathan Visweshwar, MD4; Andrew D. Leavitt, MD5; Adam Giermasz, MD, PhD6; Steven Arkin, MD7; Annie Fang, MD, PhD8; Li-Jung Tseng, MBA, PhD8; Gregory Di Russo,

Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed May 22, 2020).

EX-3.1 Exhibit 3.1 FOURTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. SANGAMO THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: FIRST: The name of the Corporation is Sangamo Therapeutics, Inc. (the “Corporation”). SEC

2018 Equity Incentive Plan (the “2018 Plan”) (incorporated by reference to Exhibit

EX-10.1 Exhibit 10.1 Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Table of Contents 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility 2 4. Options

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Collaboration and License Agreement among the Company, Biogen MA, Inc. and Biogen International GmbH, dated February 26, 2020 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed May 11, 2020).

sgmo-20200331xexfe7 Confidential Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Form of Indemnity Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed May 11, 2020).

SANGAMO THERAPUETICS, INC. INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of May , 2020, is made by and between SANGAMO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s Seventh A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commission

Stock Purchase Agreement between the Company and Biogen MA, Inc., dated February 26, 2020 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed May 11, 2020).

EXECUTION VERSION STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (“Agreement”) is entered into as of February 26, 2020 (the “Execution Date”), by and between Biogen MA, Inc.

SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND FIRST QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS BUSINESS HIGHLIGHTS AND FIRST QUARTER 2020 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Brisbane, California, May 11, 2020 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights. “I’m proud of how the Sangamo team has w

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

- DEFA14A

DEFA14A 1 d884807ddefa14a.htm DEFA14A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commissi

SGMO / Sangamo BioSciences, Inc. / BIOGEN INC. - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Sangamo Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) April 8, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

Schedule 14A

DEF 14A 1 sgmoproxyx2020xdef.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

SGMO / Sangamo BioSciences, Inc. PRE 14A - - PRE 14A

PRE 14A 1 sgmo-2020proxyxprelim.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or other jurisdiction of incorporation) (Commi

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Sangamo,” “our,” “we,” “us” and the “Company” refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. General Our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 160,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 sh

(incorporated by reference to Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed February 28, 2020)

Exhibit 10.25 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (“Agreement”) made as of the 6th day of June 2019 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Gary Loeb (“Executive”) (collectively, the “Parties”). R E C I T A L S WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and condit

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company Gendaq Limited (U.K.) Ceregene Inc. (Delaware) Sangamo Therapeutics France S.A.S. (France)

SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 8 a.m. Eastern Time

EX-99.1 Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Conference Call and Webcast Scheduled for 8 a.m. Eastern Time Brisbane, California, February 28, 2020 – Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. “This quarter marked an

Employment Agreement between the Company and Rolf Andrew (Andy) Ramelmeier effective as of November 1, 2017 (incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K filed February 28, 2020).

Exhibit 10.26 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (“Agreement”) made as of the 1st day of November, 2017 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Andy Ramelmeier (“Executive”) (collectively, the “Parties”). R E C I T A L S WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms

Employment Agreement between the Company and Sung Lee effective as of October 31, 2019.

Exhibit 10.24 EXECUTIVE EMPLOYMENT AGREEMENT Employment Agreement (“Agreement”) made as of the 21st day of October by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Sung Lee (“Executive”) (collectively, the “Parties”). R E C I T A L S WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditio

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30171 SANGAMO THERAPEUTICS, INC